<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060822</url>
  </required_header>
  <id_info>
    <org_study_id>HEC585-P-03</org_study_id>
    <nct_id>NCT05060822</nct_id>
  </id_info>
  <brief_title>Phase ll Study of HEC585 in Patients With IPF</brief_title>
  <official_title>A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in&#xD;
      patients with idiopathic pulmonary fibrosis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">May 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo-controlled (double-blind design), active comparator-controlled (open-label design)，parallel-group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Week 24 in %FVC compared with placebo</measure>
    <time_frame>24 Weeks</time_frame>
    <description>change in %FVC, measured using Spirometer, from baseline to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 24 in %FVC compared with Pirfenidone</measure>
    <time_frame>24 Weeks</time_frame>
    <description>change in %FVC, measured using Spirometer, from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in %FVC compared with placebo/ Pirfenidone</measure>
    <time_frame>12 Weeks</time_frame>
    <description>change in %FVC, measured using Spirometer, from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an absolute decline from baseline in FVC (% predicted) of &gt; 10%</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The proportion of subjects whose %FVC decline from baseline by more than 10% in each treatment group at W24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first acute IPF exacerbation</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPF related mortality</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of 6MWT results</measure>
    <time_frame>12 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of SGRQ scores</measure>
    <time_frame>12 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of DLco (Hb correction)</measure>
    <time_frame>12 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of resting SpO2</measure>
    <time_frame>12 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>HEC585 dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 dose A once daily, up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HEC585 dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 dose B once daily, up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HEC585 dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 dose C once daily, up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pirfenidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: pirfenidone three times a day (target dose), up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: placebo once daily, up to 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC585</intervention_name>
    <description>HEC585 Tablets，once daily</description>
    <arm_group_label>HEC585 dose A</arm_group_label>
    <arm_group_label>HEC585 dose B</arm_group_label>
    <arm_group_label>HEC585 dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone，three times a day</description>
    <arm_group_label>pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo，once daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteer to participate in this clinical study and sign the ICF before the study&#xD;
             begins;&#xD;
&#xD;
          -  Aged 40-80 (including 40 and 80) ;&#xD;
&#xD;
          -  Female or male subjects with child-bearing potential who agree and promise to take&#xD;
             effective contraceptive measures;&#xD;
&#xD;
          -  Diagnosed with IPF according to the Official ATS/ERS/JRS/ALAT Clinical Practice&#xD;
             Guideline for IPF Diagnosis (2018);&#xD;
&#xD;
          -  FEV1/FVC ≥ 0.7;&#xD;
&#xD;
          -  FVC ≥ 45% predicted;&#xD;
&#xD;
          -  DLCO corrected for Haemoglobin (Hb) ≥ 30% predicted of normal;&#xD;
&#xD;
          -  In the opinion of the Investigator, subjects are willing and able to comply with the&#xD;
             protocol requirements and attend the visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the Investigator, subjects underwent significant deterioration in&#xD;
             IPF within one month before randomization;&#xD;
&#xD;
          -  Interstitial lung disease caused by other known causes;&#xD;
&#xD;
          -  Any bacterial, viral, parasitic or fungal infection that needs to be treated at&#xD;
             screening;&#xD;
&#xD;
          -  Expected to receive lung transplantation during the study;&#xD;
&#xD;
          -  Expected survival is less than 6 months;&#xD;
&#xD;
          -  History of tumors within 5 years before screening (except for localized cancers such&#xD;
             as basal cell carcinoma);&#xD;
&#xD;
          -  Moderate to severe hepatic insufficiency (Child-Pugh grade B or C, see Appendix 4);&#xD;
&#xD;
          -  History of unstable or worsening heart disease within 6 months before screening;&#xD;
&#xD;
          -  Cannot perform 6MWT or PFT;&#xD;
&#xD;
          -  Allergic to any component of HEC585 Tablets or pirfenidone tablets;&#xD;
&#xD;
          -  Participated in other clinical study and received the last dose within 3 months before&#xD;
             screening;&#xD;
&#xD;
          -  Pregnant or breastfeeding;&#xD;
&#xD;
          -  History of smoking within 3 months before screening or are unwilling to quit smoking&#xD;
             during the study;&#xD;
&#xD;
          -  Subjects often drink alcohol within 6 months before the screening (drink more than 21&#xD;
             units of alcohol a week), or refuse to reduce alcohol intake during the study;&#xD;
&#xD;
          -  History of drug abuse within 6 months before the screening;&#xD;
&#xD;
          -  Family or personal history of QT prolongation syndrome;&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would compromise the safety or&#xD;
             compliance of the subject, or prevent the subject from completing the study.&#xD;
&#xD;
          -  TBil &gt; 1.5 × ULN or AST or ALT &gt; 2 × ULN;&#xD;
&#xD;
          -  CLcr &lt; 50 mL/min;&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) antibody is positive;&#xD;
&#xD;
          -  Uncontrolled hepatitis B virus infection or hepatitis C virus infection;&#xD;
&#xD;
          -  QTcF &gt; 480 ms.&#xD;
&#xD;
          -  Subjects have received any of the following treatments within 28 days before&#xD;
             randomization:&#xD;
&#xD;
               1. Any cytotoxic drug or immunosuppressant&#xD;
&#xD;
               2. Therapeutic drugs for IPF, including but not limited to pirfenidone, nintedanib,&#xD;
                  prednisone at &gt; 15 mg/d or other glucocorticoids of the equivalent dose,&#xD;
                  N-acetylcysteine at &gt; 600 mg/d.&#xD;
&#xD;
               3. Moderate and strong inhibitor or strong inducer of CYP1A2.&#xD;
&#xD;
               4. Strong inducers or strong CYP3A4 inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>HuaPing Dai, MD</last_name>
    <phone>010-84206278</phone>
    <email>daihuaping@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

